Middle East Pharmaceutical Industries Company (4016.SR) — Income statement
Revenue, gross profit, operating income, net income, and EPS for Middle East Pharmaceutical Industries Company — annual and quarterly.
| Metric (SAR Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 460↑16.9% | 394↑16.4% | 338↑11.8% | 303↑5.4% | 287 | |
| Cost of Revenue | 174↑15.3% | 151↑14.6% | 131↑5.1% | 125↑5.9% | 118 | |
| Gross Profit | 287↑17.9% | 243↑17.5% | 207↑16.5% | 178↑5.0% | 169 | |
| Operating Expenses | ||||||
| R&D Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| General & Administrative Expenses | 0.00↓100.0% | 24↓51.9% | 49↑15.7% | 43↑21.7% | 35 | |
| Selling & Marketing Expenses | 0.00↓100.0% | 47↓41.4% | 81↑14.5% | 70↑15.1% | 61 | |
| SG&A Expenses | 178↑151.7% | 71↓45.2% | 129↑20.6% | 107↑15.8% | 93 | |
| Other Expenses | 0.00↓100.0% | 81↑12965.0% | -0.63 | 0.00 | 0.00 | |
| Operating Expenses | 178↑17.2% | 152↑18.3% | 129↑20.0% | 107↑15.8% | 93 | |
| Total Costs & Expenses | 352↑16.2% | 303↑16.4% | 260↑12.0% | 232↑10.3% | 211 | |
| Operating Results | ||||||
| Operating Income | 108↑19.1% | 91↑16.3% | 78↑11.3% | 70↓8.1% | 77 | |
| Depreciation & Amortization | 0.00↓100.0% | 16↑108.2% | 8↓28.4% | 11↑11.0% | 10 | |
| EBITDA | 108↑1.4% | 107↑25.5% | 85↑4.9% | 81↓2.2% | 83 | |
| EBIT | 108↑19.1% | 91↑17.4% | 78↑10.0% | 71↓3.9% | 73 | |
| Interest & Other Income | ||||||
| Net Interest Income | -5↓27.2% | -4 | 0.00 | 0.00 | 0.00 | |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Interest Expense | 5↑27.2% | 4↓47.4% | 7↑19.8% | 6↑98.2% | 3 | |
| Non-Operating Income | 0.00↑100.0% | -0.14↓120.0% | 0.72↑18003000.0% | -0.00↓100.0% | 0.50 | |
| Other Income / Expenses | -5↑1.0% | -5↑31.2% | -7↓24.3% | -5↓59.4% | -3 | |
| Income Before Tax | 104↑20.1% | 86↑20.9% | 71↑9.9% | 65↓7.7% | 70 | |
| Income Tax Expense | 7↑3.5% | 7↑15.8% | 6↑0.7% | 6↑33.4% | 4 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | 97↑21.5% | 80↑21.3% | 66↑10.7% | 59↓10.3% | 66 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | 97↑21.5% | 80↑21.3% | 66↑10.7% | 59↓10.3% | 66 | |
| Bottom-Line Net Income | 97↑21.5% | 80↑21.3% | 66↑10.7% | 59↓10.3% | 66 | |
| EPS (Basic) | 2.77↑21.5% | 2.28↑21.3% | 1.88↑10.8% | 1.70↓10.3% | 1.89 | |
| EPS (Diluted) | 2.77↑21.5% | 2.28↑21.3% | 1.88↑10.8% | 1.70↓10.3% | 1.89 | |
| Weighted Average Shares | 35↓22.1% | 45↑28.4% | 35↑0.0% | 35↑0.0% | 35 | |
| Weighted Average Diluted Shares | 35↓22.1% | 45↑28.4% | 35↑0.0% | 35↑0.0% | 35 | |
* All figures in Millions of SAR, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.